Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Afraxis Inc.

This article was originally published in Start Up

Executive Summary

Afraxis Inc. is developing p21-activated kinase (PAK) inhibitors, initially for Fragile X syndrome, a genetic condition involving changes in the X chromosome that can lead to cognitive impairment and autism-like behaviors. The start-up thinks treatment of this orphan indication may be a gateway to developing PAK inhibitors for closely related conditions, such as autism and other central nervous system disorders like Alzheimer's disease and schizophrenia.

You may also be interested in...



Afraxis Hopes Experimental Fragile X Drug Could Apply To Other CNS Diseases

Biotech believes that inactivation of p21-activated kinase may address underlying cause of Fragile X syndrome.

Afraxis Hopes Experimental Fragile X Drug Could Apply To Other CNS Diseases

Biotech believes that inactivation of p21-activated kinase may address underlying cause of Fragile X syndrome.

Ultragenyx Pharmaceutical LLC

Biotech veteran Emil Kakkis founded Ultragenyx Pharmaceutical LLC to develop treatments for rare disorders. First up: a potential therapy for hereditary inclusion body myopathies. There are several variants of this neuromuscular disorder, which causes progressive muscle weakness. By the end of the disease course, patients can be almost quadriplegic in terms of motor function. Ultragenyx is betting it can help restore muscle function in people diagnosed with HIBM by providing a continuous and steady source of sialic acid, likely through thrice-daily oral administration.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM013195

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel